During this discussion, a KOL from the US East Coast provides valuable insights. Alongside discussing the GOLD guidelines, the KOL also gives an overview of inhaler market shares. Additionally, the KOL shares their strategies for patient selection when considering Dupixent and other emerging biologics such as anti-IL-5, anti-IL-33, and anti-TSLP antibodies within the COPD treatment landscape. 

This interview was conducted on 14 May 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.